Tucatinib (ONT-380) progressing in pivotal demo against HER2+ breast cancer

Stage 1 clinical trial data published this week in the journal Clinical Malignancy Research show early promise from the investigational anti-cancer agent tucatinib (formerly ONT-380) against HER2+ breast cancer. The particular 50 women treated had advanced despite a median 5 earlier treatment regimens. Twenty-seven percent of the heavily pretreated patients saw scientific benefit from the drug, with at least “stable disease” at 24 or more days after the start of treatment. These data led to two subsequent Phase Ib studies, resulting in tucatinib earning FDA fast-track status and the enlargement of this study once meant simply to demonstrate drug safety into the “pivotal” trial that will determine approval. Related Posts:Fox Chase trial tests promising therapy in early breast…Cleveland Clinic’s preventive breast cancer vaccine…Radioimmunotherapy, Gemcitabine combination shows early…Drug shows surprising efficacy as therapy for chronic…Combining epigenetic therapies with immunotherapies likely…The post Tucatinib (ONT-380) progressing in pivotal demo against HER2+ breast cancer appeared first on My Irritable Bowel Syndrome Story.
Source: My Irritable Bowel Syndrome Story - Category: Gastroenterology Authors: Tags: IBS News Source Type: blogs